Company Overview and News


Add BLUE
to your dashboard

Headline News

bluebird bio (BLUE) Soars: Stock Adds 7.3% in Session

1h zacks
bluebird bio, Inc.(BLUE - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 3.8% in the past one-month time frame. (54-0)

Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

2018-01-17 zacks
Per reports, biotech bigwig Celgene Corporation (CELG - Free Report) is looking to acquire smaller biotech Juno Therapeutics (JUNO - Free Report) . (93-0)

Juno Therapeutics Surges on Report of Celgene Deal Talks

2018-01-17 bloomberg
Juno Therapeutics Inc. surged in after-hours trading after the Wall Street Journal reported that Celgene Corp. was in talks to buy the Seattle-based drugmaker. (73-0)

Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-13 in.reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-12 reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Drugmakers see a pricing blueprint in an US$850,000 gene therapy - Channel NewsAsia

2018-01-12 channelnewsasia
SAN FRANCISCO: Global drugmakers are looking to a tiny biotech's US$850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Your Daily Pharma Scoop: Roche Highlights Pipeline, GenSight Gets Nod To Start Trial, Bluebird Presents At JPM

2018-01-11 seekingalpha
Roche is confident that its newly launched product and pipeline can offset loss of revenue from biosimilar competition. (86-0)

Celgene Provides 2017 Preliminary Results & 2018 View

2018-01-09 zacks
Celgene Corporation (CELG - Free Report) provided preliminary results for 2017 and guidance for 2018 at the 36th Annual J.P. Morgan Healthcare Conference. (82-0)

Biotech Beast Positions For 2018: A Rising Tide Lifts Some Boats More Than Others

2017-12-31 seekingalpha
While the dip in drug approvals which occurred in 2016 was rectified in 2017, there is still a deficit in M&A. (252-4)

ROTY Edition 1 Volume 66: GW Pharmaceuticals Gets Closer To The Finish Line - And Other Updates

2017-12-28 seekingalpha
ROTY has gotten off to a great start and much of that is due to support from readers. In coming months the discussion will shift to future formats and changes. (521-2)

2018 Should Be Better for Celgene Corporation and CELG Stock

2017-12-28 investorplace
To say 2017 was a tough year for Celgene Corporation (NASDAQ:CELG) and CELG stock would be a considerable understatement. Despite starting the year on the right foot and advancing 22% as of late September, bad R&D news that month sent the stock lower to the tune of 33% from that peak. (68-0)

5 of the Best-Performing Biotech Stocks of 2017

2017-12-28 zacks
With just a few days left for the year to end, it can be said that 2017 turned out to be a pretty good year for the biotech sector. The sector had been struggling due to several issues including the drug pricing controversy, mixed results, slower-than-expected new product launches, increasing competition and pipeline setbacks. However, with investors being more comfortable about the drug pricing controversy this year, the focus is now more on the fundamentals of the sector. (157-1)

Global Blood Therapeutics: The Significance Of ASH Updates

2017-12-27 seekingalpha
There seems to be an established tradition for the stock to drop after its ASH presentation. (45-0)

5 Immuno-Oncology Developments To Watch In 2018

2017-12-26 forbes
Bluebird Bio CEO Nick Leschly speaking at the recent Forbes Healthcare Summit. Bluebird is one of the companies drumming up excitement for immuno-oncology. (17-1)

4 Biotech Stocks That More Than Doubled This Year

2017-12-22 zacks
The biotech industry has been on the comeback trail in 2017 after facing a number of challenges last year including pricing pressure, rising competition, pipeline setbacks, pricing pressure, slowdown in growth of mature products and generic competition for certain key drugs. (146-1)

CUSIP: 09609G100